Competitive Landscape Assessment
BackgroundClient's drug was in Phase I and would likely be third to market. Innovator of the class was already on the market, a true breakthrough and a blockbuster drug. A second competitor was preparing to launch next, but its launch strategy and timing were uncertain. A third product also appeared to be exploring an indication that might be a threat, but its future clinical plans were unknown.
"You gave us great depth of insight into what our competitors are likely to do and the challenges we have. This will impact our clinical decision making and will be something the whole team will be referencing repeatedly."